Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$25.93
-0.1%
$26.88
$22.88
$28.75
$147.76B0.3541.72 million shs9.58 million shs
Redfin Corporation stock logo
RDFN
Redfin
$11.19
$10.90
$8.59
$11.84
$1.43B2.387.41 million shs33,889 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+0.57%+0.72%-5.09%-2.74%+12.43%
Redfin Corporation stock logo
RDFN
Redfin
0.00%0.00%0.00%0.00%+16.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$25.93
-0.1%
$26.88
$22.88
$28.75
$147.76B0.3541.72 million shs9.58 million shs
Redfin Corporation stock logo
RDFN
Redfin
$11.19
$10.90
$8.59
$11.84
$1.43B2.387.41 million shs33,889 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+0.57%+0.72%-5.09%-2.74%+12.43%
Redfin Corporation stock logo
RDFN
Redfin
0.00%0.00%0.00%0.00%+16.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.6110.36% Upside
Redfin Corporation stock logo
RDFN
Redfin
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RDFN and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/20/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$25.00
4/16/2026
Pfizer Inc. stock logo
PFE
Pfizer
Initiated CoverageOutperform$33.00
4/13/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$25.00 ➝ $27.00
4/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetEqual Weight$27.00 ➝ $28.00
4/9/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetNeutral$27.00 ➝ $26.00
3/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetBuy$35.00 ➝ $36.00
3/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
Set Price TargetPositive$27.00
(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.36$4.42 per share5.87$15.86 per share1.63
Redfin Corporation stock logo
RDFN
Redfin
$1.04B1.38N/AN/A($0.67) per share-16.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.799.06N/A11.83%19.44%8.41%8/4/2026 (Estimated)
Redfin Corporation stock logo
RDFN
Redfin
-$164.80M-$1.53N/AN/AN/A-18.35%N/A-17.24%N/A

Latest RDFN and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.63%-13.20%131.30%16 Years
Redfin Corporation stock logo
RDFN
Redfin
N/AN/AN/AN/AN/A

Latest RDFN and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Redfin Corporation stock logo
RDFN
Redfin
N/A
1.16
1.16

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Redfin Corporation stock logo
RDFN
Redfin
61.07%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Redfin Corporation stock logo
RDFN
Redfin
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Redfin Corporation stock logo
RDFN
Redfin
5,570128.03 million122.40 millionOptionable

Recent News About These Companies

Redfin data shows trouble for US housing market
Rocket Companies: Ideal Candidate For A Short Squeeze

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pfizer stock logo

Pfizer NYSE:PFE

$25.92 -0.03 (-0.10%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Redfin stock logo

Redfin NASDAQ:RDFN

Redfin Corporation operates as a residential real estate brokerage company in the United States and Canada. The company operates an online real estate marketplace and provides real estate services, including assisting individuals in the purchase or sell of home. It also provides title and settlement services; and originates and sells mortgages. In addition, the company uses digital platforms to connect consumers with rental properties. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.